Literature DB >> 3898289

Thymopentin: stability considerations and potency by various routes of administration.

T K Audhya, G Goldstein.   

Abstract

Thymopentin, the synthetic pentapeptide Arg-Lys-Asp-Val-Tyr corresponding to amino acids 32-36 of thymopoietin, was rapidly degraded in human plasma (T 1/2 = 30 s) and this was shown to be due to proteolytic enzymes in plasma. The biological potency of thymopentin varied greatly with the route of administration, a finding possibly related to its short half-life. Intravenous infusion provided the most potent and bolus intraperitoneal injection the least potent mode of administration. Thus the route and rate of administration are critical factors in determining the effective dose being received by the animal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898289     DOI: 10.1007/bf02919052

Source DB:  PubMed          Journal:  Surv Immunol Res        ISSN: 0252-9564


  25 in total

1.  Effect of continuous insulin infusion with an implantable seven-day minipump in the diabetic Chinese hamster.

Authors:  B J Frankel; F G Schmid; G M Grodsky
Journal:  Endocrinology       Date:  1979-05       Impact factor: 4.736

2.  Contrasting effects of thymopentin and splenopentin on the capacity of female mice to reject syngeneic male skin.

Authors:  E H Goldberg; G Goldstein; D B Harman; E A Boyse
Journal:  Transplantation       Date:  1984-07       Impact factor: 4.939

3.  Thymopentin (TP-5) potency in vivo is enhanced by slow infusion.

Authors:  T Audhya; G Goldstein
Journal:  Int J Pept Protein Res       Date:  1983-11

4.  Restoration of the impaired lymphocyte stimulation in old people by thymopoietin pentapeptide.

Authors:  H Verhaegen; W De Cock; J De Cree; G Goldstein
Journal:  J Clin Lab Immunol       Date:  1981-09

5.  Effect of the TP5 analogue of thymopoietin on the rejection of male skin by aged and thymectomized female mice.

Authors:  E H Goldberg; G Goldstein; E A Boyse; M P Scheid
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen.

Authors:  T Audhya; M P Scheid; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

7.  Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis.

Authors:  K Kang; K D Cooper; J M Hanifin
Journal:  J Am Acad Dermatol       Date:  1983-03       Impact factor: 11.527

8.  Comparative efficacy of various routes of administration of thymopentin (TP-5) with consideration of degradative mechanisms.

Authors:  T Audhya; G Goldstein
Journal:  Int J Pept Protein Res       Date:  1983-08

9.  Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis.

Authors:  E M Veys; E C Huskisson; M Rosenthal; T L Vischer; H Mielants; P A Thrower; J Scott; H Ott; H Scheijgrond; J Symoens
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

10.  Immunological studies of aging. IV. The contribution of thymic involution to the immune deficiencies of aging mice and reversal with thymopoietin32-36.

Authors:  M C Weksler; J D Innes; G Goldstein
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  3 in total

1.  An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.

Authors:  N Giordano; G Biasi; A Taddeo; R Marcolongo; D Bertelletti
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

2.  Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.

Authors:  Ting Zhang; Xian-Yan Qin; Xi Cao; Wen-Hao Li; Tao Gong; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-07-12       Impact factor: 6.150

3.  Thymopentin treatment of selective IgA deficiency.

Authors:  M Fiorilli; I Quinti; G Russi; R Seminara; B Ensoli; F Aiuti
Journal:  Surv Immunol Res       Date:  1985
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.